241 related articles for article (PubMed ID: 35523936)
21. Reprogramming of glutamine metabolism via glutamine synthetase silencing induces cisplatin resistance in A2780 ovarian cancer cells.
Guo J; Satoh K; Tabata S; Mori M; Tomita M; Soga T
BMC Cancer; 2021 Feb; 21(1):174. PubMed ID: 33596851
[TBL] [Abstract][Full Text] [Related]
22. DYRK2 regulates epithelial-mesenchymal-transition and chemosensitivity through Snail degradation in ovarian serous adenocarcinoma.
Yamaguchi N; Mimoto R; Yanaihara N; Imawari Y; Hirooka S; Okamoto A; Yoshida K
Tumour Biol; 2015 Aug; 36(8):5913-23. PubMed ID: 25712377
[TBL] [Abstract][Full Text] [Related]
23. Epigenetic Regulation of the Homeobox Gene MSX1 Associates with Platinum-Resistant Disease in High-Grade Serous Epithelial Ovarian Cancer.
Bonito NA; Borley J; Wilhelm-Benartzi CS; Ghaem-Maghami S; Brown R
Clin Cancer Res; 2016 Jun; 22(12):3097-3104. PubMed ID: 26763252
[TBL] [Abstract][Full Text] [Related]
24. Loss of discoidin domain receptor 1 (DDR1) via CpG methylation during EMT in epithelial ovarian cancer.
Chung VY; Tan TZ; Huang RL; Lai HC; Huang RY
Gene; 2017 Nov; 635():9-15. PubMed ID: 28887161
[TBL] [Abstract][Full Text] [Related]
25. Identifying novel hypoxia-associated markers of chemoresistance in ovarian cancer.
McEvoy LM; O'Toole SA; Spillane CD; Martin CM; Gallagher MF; Stordal B; Blackshields G; Sheils O; O'Leary JJ
BMC Cancer; 2015 Jul; 15():547. PubMed ID: 26205780
[TBL] [Abstract][Full Text] [Related]
26. Epithelial‑mesenchymal transition induced by bone morphogenetic protein 9 hinders cisplatin efficacy in ovarian cancer cells.
Wang Y; Yang B; Zhao J; Yu X; Liu X; Zhang L; Zhang Y; Li X; Zhai Z
Mol Med Rep; 2019 Mar; 19(3):1501-1508. PubMed ID: 30628686
[TBL] [Abstract][Full Text] [Related]
27. Establishment of Acquired Cisplatin Resistance in Ovarian Cancer Cell Lines Characterized by Enriched Metastatic Properties with Increased Twist Expression.
Bahar E; Kim JY; Kim HS; Yoon H
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33076245
[TBL] [Abstract][Full Text] [Related]
28. Elevated MAL expression is accompanied by promoter hypomethylation and platinum resistance in epithelial ovarian cancer.
Lee PS; Teaberry VS; Bland AE; Huang Z; Whitaker RS; Baba T; Fujii S; Secord AA; Berchuck A; Murphy SK
Int J Cancer; 2010 Mar; 126(6):1378-89. PubMed ID: 19642140
[TBL] [Abstract][Full Text] [Related]
29. [E-cadherin promoter methylation and demethylation in epithelial ovarian carcinoma cells].
Qu PP; Shi Z; Li N
Zhonghua Fu Chan Ke Za Zhi; 2009 Jul; 44(7):538-41. PubMed ID: 19957556
[TBL] [Abstract][Full Text] [Related]
30. FOXM1 confers to epithelial-mesenchymal transition, stemness and chemoresistance in epithelial ovarian carcinoma cells.
Chiu WT; Huang YF; Tsai HY; Chen CC; Chang CH; Huang SC; Hsu KF; Chou CY
Oncotarget; 2015 Feb; 6(4):2349-65. PubMed ID: 25537512
[TBL] [Abstract][Full Text] [Related]
31. A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer.
Strathdee G; MacKean MJ; Illand M; Brown R
Oncogene; 1999 Apr; 18(14):2335-41. PubMed ID: 10327053
[TBL] [Abstract][Full Text] [Related]
32. Genes suppressed by DNA methylation in non-small cell lung cancer reveal the epigenetics of epithelial-mesenchymal transition.
Lin SH; Wang J; Saintigny P; Wu CC; Giri U; Zhang J; Menju T; Diao L; Byers L; Weinstein JN; Coombes KR; Girard L; Komaki R; Wistuba II; Date H; Minna JD; Heymach JV
BMC Genomics; 2014 Dec; 15(1):1079. PubMed ID: 25486910
[TBL] [Abstract][Full Text] [Related]
33. Caffeic acid phenethyl ester activates pro-apoptotic and epithelial-mesenchymal transition-related genes in ovarian cancer cells A2780 and A2780cis.
Gherman C; Braicu OL; Zanoaga O; Jurj A; Pileczki V; Maralani M; Drigla F; Braicu C; Budisan L; Achimas-Cadariu P; Berindan-Neagoe I
Mol Cell Biochem; 2016 Feb; 413(1-2):189-98. PubMed ID: 26838168
[TBL] [Abstract][Full Text] [Related]
34. Forkhead Box Protein C2 Promotes Epithelial-Mesenchymal Transition, Migration and Invasion in Cisplatin-Resistant Human Ovarian Cancer Cell Line (SKOV3/CDDP).
Li C; Ding H; Tian J; Wu L; Wang Y; Xing Y; Chen M
Cell Physiol Biochem; 2016; 39(3):1098-110. PubMed ID: 27562816
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of PI3K/Akt/mTOR signaling pathway alleviates ovarian cancer chemoresistance through reversing epithelial-mesenchymal transition and decreasing cancer stem cell marker expression.
Deng J; Bai X; Feng X; Ni J; Beretov J; Graham P; Li Y
BMC Cancer; 2019 Jun; 19(1):618. PubMed ID: 31234823
[TBL] [Abstract][Full Text] [Related]
36. The Impact of the Low Molecular Weight Heparin Tinzaparin on the Sensitization of Cisplatin-Resistant Ovarian Cancers-Preclinical In Vivo Evaluation in Xenograft Tumor Models.
Mueller T; Pfankuchen DB; Wantoch von Rekowski K; Schlesinger M; Reipsch F; Bendas G
Molecules; 2017 May; 22(5):. PubMed ID: 28467373
[TBL] [Abstract][Full Text] [Related]
37. KRAB zinc-finger protein 382 regulates epithelial-mesenchymal transition and functions as a tumor suppressor, but is silenced by CpG methylation in gastric cancer.
Pei L; He X; Li S; Sun R; Xiang Q; Ren G; Xiang T
Int J Oncol; 2018 Sep; 53(3):961-972. PubMed ID: 29956735
[TBL] [Abstract][Full Text] [Related]
38. Epithelial-mesenchymal status renders differential responses to cisplatin in ovarian cancer.
Miow QH; Tan TZ; Ye J; Lau JA; Yokomizo T; Thiery JP; Mori S
Oncogene; 2015 Apr; 34(15):1899-907. PubMed ID: 24858042
[TBL] [Abstract][Full Text] [Related]
39. Rapamycin enhanced the antitumor efficacy of oxaliplatin in cisplatin-resistant ovarian cancer cells A2780cis both in vitro and in vivo.
Liu J; Zhang L; Zhang X; Xing X
J Chemother; 2015; 27(6):358-64. PubMed ID: 25976336
[TBL] [Abstract][Full Text] [Related]
40. CD24 expression is a marker for predicting clinical outcome and regulates the epithelial-mesenchymal transition in ovarian cancer via both the Akt and ERK pathways.
Nakamura K; Terai Y; Tanabe A; Ono YJ; Hayashi M; Maeda K; Fujiwara S; Ashihara K; Nakamura M; Tanaka Y; Tanaka T; Tsunetoh S; Sasaki H; Ohmichi M
Oncol Rep; 2017 Jun; 37(6):3189-3200. PubMed ID: 28440503
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
